Can-Fite BioPharma has been approved to enroll U.S. patients in its ongoing Phase 2b clinical trial of the oral…
Articles by Lindsey Shapiro, PhD
Interim analyses of data from Phase 2 clinical trials testing Mirum Pharmaceuticals’ oral therapy candidate volixibat in people with…
Treatment with Livmarli (maralixibat) leads to significant clinical benefits for people with progressive familial intrahepatic cholestasis (PFIC) across…
Global rates for evaluating chronic hepatitis B and starting appropriate treatment are lower than they should be, especially among…
Daily treatment with Bylvay (odevixibat) safely and effectively eases itching and lowers blood bile acid levels, a sign of liver…
Throughout May, the U.S. Centers for Disease Control and Prevention (CDC) will work with public health partners to raise…
Gilead Sciences has awarded $4 million in funding via its ALL4LIVER grant program to organizations worldwide whose community-based efforts…
FXR314, an investigational oral therapy, safely and effectively reduced liver fat content in adults with a severe form of…
The approval of Rezdiffra (resmetirom) last month in the U.S. as the first ever treatment for nonalcoholic steatohepatitis (NASH),…
Five-year-old Sadie Sellers, who was born with biliary atresia, is the focus of a fundraising event designed to raise…